Table 2.
Receptor | G protein | Recent studies and therapeutic outcomes | References |
---|---|---|---|
A1 | Gi/o | Deletion of A1 receptor exacerbated the neuronal loss, convulsions and subsequent mortality in adult male and female C57BL/6 mice after unilateral intrahippocampal injection of kainate (1 nmol). | Fedele et al., 2006 |
The proconvulsive effect of A1 receptor ablation was aggravated by experimental traumatic brain injury in adult male and female C57BL/6 mice. | Kochanek et al., 2006 | ||
Adenosine A1 receptor deficiency mice (adult male C57BL/6) developed spontaneous seizures with homozygous knockout mice showing higher frequency and longer duration of electrographic seizures than their heterozygous cohorts. | Li et al., 2007 | ||
A2A | Gs | Focal bilateral microinjection of A2A receptor agonist CGS-21680 (up to 3 μg/side) increased, whereas A2A antagonist sCh-58261 (up to 20 μg/side) decreased, the number and duration of the unprovoked spike-wave discharges in young and adult male WAG/Rij rats in a dose-dependent manner. | D’Alimonte et al., 2009 |
Ablation of A2A receptor decreased intensity and frequency of seizures induced by PTZ or pilocarpine in adult CD1 mice. | El Yacoubi et al., 2009 | ||
A2A selective agonist CPCA (2 mg/kg, i.p.) decreased the mortality and lowered the seizure threshold in a hyperthermia-induced seizure model in young male Lewis rats. | Fukuda et al., 2011 | ||
A2B | Gs | Delivery of nonselective adenosine receptor agonist NECA (0.1 mM) into the striatum of adult BALB/c mice via reverse microdialysis increased IL-6, and this cytokine elevation was blocked by A2B receptor antagonist MRS-1706 (0.01 mM). | Vazquez et al., 2008 |
A3 | Gi/o | Treatment with selective A3 adenosine receptor agonist IB-MEC (100 μg/kg, i.p.) prior to NMDA or PTZ-induced seizures in adult male C57BL/6 mice decreased the percentage of animals with convulsions, delayed seizure onset, reduced neurological impairment, and increased animal survival. | Von Lubitz et al., 1995 |
Abbreviations: IL-6, interleukin 6; NECA, 5′-N-ethylcarboxamidoadenosine; NMDA, N-methyl-D-aspartic acid; PTZ, pentylenetetrazol.